Costa Rica biotech where CONIS takes 24 months for trial approval, CCSS only buys from approved international pharma, and Medtronic/Boston Scientific use US regulatory pathways
Years-long decline before final shutdown · Fatal mistake: Costa Rica biotech: CONIS (CCSS bioethics committee) clinical trial approval process took 18-24 months. CCSS (national health insurance, 95% of population) had procurement for approved international pharmaceutical suppliers only. Ministerio de Salud device registration required 24+ months. Costa Rica's medical device exports (Medtronic, Boston Scientific factories) used US parent regulatory pathways. Local biotech had no commercial pathway.
Evaluating only BiotechCR’s profile at its peak — without knowing the outcome — the model ranked Competition as the #1 likely cause. Documented cause: Distribution.
Key Events Timeline
FOUNDING
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
BiotechCR built biotech device in CR. CONIS 24 months. CCSS only buys FDA/CE approved. Ministerio device registration 24+ months. 48-month total regulatory path.
Lesson
“Costa Rica biotech must pursue FDA 510(k) clearance rather than local CONIS/Ministerio registration — FDA clearance provides both US market access and CCSS procurement eligibility, while local-only approval provides neither.”
Failure anatomy
Collapse type
Slow Death
🐌 LOW
Hype cycle
None
Moat type
Technology
Fatal mistake
Costa Rica biotech: CONIS (CCSS bioethics committee) clinical trial approval process took 18-24 months. CCSS (national health insurance, 95% of population) had procurement for approved international pharmaceutical suppliers only. Ministerio de Salud device registration required 24+ months. Costa Rica's medical device exports (Medtronic, Boston Scientific factories) used US parent regulatory pathways. Local biotech had no commercial pathway.